8-K: BioXcel Therapeutics Reports Q4 and Full Year 2024 Financial Results; Enrollment Exceeds 60% in SERENITY At-Home Phase 3 Trial

BioXcel Therapeutics announces its Q4 and full year 2024 financial results, highlighting progress in the SERENITY At-Home Phase 3 trial and a strengthened cash position.

Summary

• BioXcel Therapeutics reported its financial results for the fourth quarter and full year 2024.
• The company's net revenue from IGALMI was $366,000 for Q4 2024, compared to $376,000 for the same period in 2023.
• Full-year 2024 net revenue from IGALMI was $2.3 million, up from $1.4 million in 2023.
• The company's net loss for Q4 2024 was $10.9 million, compared to a net loss of $22.3 million for Q4 2023.
• For the full year 2024, BioXcel Therapeutics reported a net loss of $59.6 million, compared to a net loss of $179.1 million for 2023.
• Cash and cash equivalents totaled $29.9 million on December 31, 2024, compared to $65.2 million on December 31, 2023.
• The SERENITY At-Home Phase 3 trial has enrolled 127 patients, representing 63% of the required enrollment of 200 patients.
• Topline data from the SERENITY At-Home Phase 3 trial is expected in the second half of 2025.
• The company closed a $14 million equity financing, strengthening its cash position to approximately $35 million as of March 4, 2025.
• The FDA closed its site inspection of the TRANQUILITY II Phase 3 trial site and released an Establishment Inspection Report designating Voluntary Action Indicated for the site.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reduced net loss, increased IGALMI revenue, and progress in the SERENITY trial. However, the company still faces financial challenges and risks.

Positives

• The company's net loss decreased significantly year-over-year.
• IGALMI revenue increased year-over-year.
• The SERENITY At-Home Phase 3 trial is progressing well with over 60% enrollment.
• The company strengthened its cash position through equity financing.
• FDA inspection closure supports the reliability of TRANQUILITY II trial data.

Negatives

• The company continues to experience net losses.
• Cash and cash equivalents decreased from $65.2 million to $29.9 million year-over-year.
• Cost of goods sold increased due to higher charges for reserves for excess or obsolete inventory.
• IGALMI revenue for Q4 2024 was slightly lower than Q4 2023.

Risks

• The company's limited operating history and significant losses raise concerns about its financial stability.
• The company needs substantial additional funding and its ability to raise capital is uncertain.
• The company is dependent on the success and commercialization of IGALMI and other product candidates.
• The company faces extensive and ongoing regulatory requirements and obligations for IGALMI.
• The company's ability to enroll patients in its clinical trials is a risk factor.

Future Outlook

The company plans to advance its SERENITY and TRANQUILITY trials and supply IGALMI through existing distribution channels. Topline data from the SERENITY At-Home Phase 3 trial is expected in the second half of 2025, which is intended to support a potential sNDA submission for label expansion of IGALMI in the at-home setting.

Management Comments

• We believe that our SERENITY program presents an exciting opportunity to address a substantial unmet medical need the 23 million episodes of bipolar and schizophrenia-related agitation that occur annually in the United States at home and expand the market potential for our lead neuroscience asset BXCL501, said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
• We are pleased that patient enrollment in our SERENITY At-Home pivotal Phase 3 trial is progressing well and that we have recently strengthened our cash position to further advance this important study.

Industry Context

BioXcel Therapeutics is focused on developing treatments for agitation associated with neurological and psychiatric disorders, a significant unmet need in the neuroscience space. The company's AI-driven drug re-innovation approach aims to leverage existing drugs for new therapeutic indications. The progress in the SERENITY trial and the continued supply of IGALMI position the company to potentially expand its market presence in the treatment of agitation.

Comparison to Industry Standards

• It is difficult to compare BioXcel's results directly to industry standards without knowing the specific benchmarks for companies focused on similar indications and stages of development.
• However, the decrease in net loss and the increase in IGALMI revenue suggest positive trends compared to the company's own historical performance.
• Companies like Acadia Pharmaceuticals, which focuses on neurological disorders, could be considered a peer for comparison, but their specific financial metrics and pipeline differ significantly.
• The successful completion of the TRANQUILITY II Phase 3 trial site inspection by the FDA is a positive sign, as it demonstrates compliance with regulatory standards.

Stakeholder Impact

• Shareholders may be encouraged by the reduced net loss and progress in clinical trials.
• Patients may benefit from the continued development of treatments for agitation.
• Employees may be affected by the company's restructuring and reprioritization efforts.
• The company's financial stability impacts its ability to meet obligations to suppliers and creditors.

Next Steps

• Continue patient enrollment in the SERENITY At-Home Phase 3 trial.
• Await topline data from the SERENITY At-Home Phase 3 trial in the second half of 2025.
• Advance the TRANQUILITY program following FDA feedback.
• Continue supplying IGALMI through existing distribution channels.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, IGALMI, BXCL501, SERENITY, TRANQUILITY, Financial Results, Phase 3 Trial, Agitation, Schizophrenia, Bipolar Disorder, Alzheimers, Equity Financing, FDA